A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis (NCT06559150)
A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis
🩺 Plain-English Summary (8th-Grade Level)
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer up to 52 weeks, compared to placebo, in participants with non-cystic fibrosis bronchiectasis (NCFBE).
Who can join: Review the eligibility criteria below.
Location: Kirklin Clinic of UAB Hospital — Birmingham, Alabama
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (51 Sites)
Showing the first 25 of 51 sites.
- Kirklin Clinic of UAB Hospital — Birmingham, Alabama
- So Cal Institute for Respiratory Diseases, Inc. — Los Angeles, California
- University of California Davis Medical Center — Sacramento, California
- National Jewish Health Main Campus — Denver, Colorado
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- University of Miami — Miami, Florida
- Emory University at Saint Joseph Pulmonary Clinic — Atlanta, Georgia
- Augusta University — Augusta, Georgia
- ASHA Clinical Research — Hammond, Indiana
- University of Iowa — Iowa City, Iowa
- University of Kansas Medical Center-Kansas City — Kansas City, Kansas
- Massachusetts General Hospital- 55 Fruit St — Boston, Massachusetts
- University of Michigan Hospital — Ann Arbor, Michigan
- Mayo Clinic — Rochester, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- NYU Langone Health Pulmonary and Critical Care Associates, P.C. - BRANY - PPDS — New York, New York
- University of North Carolina — Chapel Hill, North Carolina
- Accellacare of Wilmington — Wilmington, North Carolina
- Southeastern Research Center — Winston-Salem, North Carolina
- Ohio State University — Columbus, Ohio
- Oregon Health and Science University — Portland, Oregon
- Temple University Hospital — Philadelphia, Pennsylvania
- Medical University of South Carolina (MUSC) - PPDS — Charleston, South Carolina
- Velocity Clinical Research - Spartanburg - PPDS — Spartanburg, South Carolina
- Velocity Clinical Research - Union - PPDS — Union, South Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-cystic Fibrosis Bronchiectasis
- A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease — Birmingham, Alabama
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis — Plantation, Florida
- Breathing Training and Exercise Capacity in Non-CFB — Jacksonville, Florida
Explore by condition: All Non-cystic Fibrosis Bronchiectasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.